Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2021-01-27 Director's Dealing
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-01-27 English
FORM 4/A SUBMISSION
Director's Dealing
2021-01-27 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to SEC Rule 424(b)(5) related to a shelf registration statement for the issuance and sale of up to $500 million of common stock by Novavax, Inc. It includes detailed information about the offering, use of proceeds, risk factors, plan of distribution, and other related disclosures. The document is a formal offering document used to raise capital through equity issuance. This type of filing corresponds to a Capital/Financing Update as it provides updates on the company's fundraising activities and capital structure changes. It is not an annual or quarterly report, audit report, earnings release, or any other category. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement but a full prospectus supplement.
2021-01-22 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports on material definitive agreements entered into by the company (Novavax, Inc.) and other significant events such as a sales agreement for shares. The content includes descriptions of agreements, legal opinions, and sales agreements, typical of a current report updating investors on material events. It is not an annual or quarterly report, audit report, earnings release, or other specific report types. The Form 8-K is a regulatory filing used to disclose material events promptly. Therefore, the document fits the category of Regulatory Filings (RNS). The document length (8156 characters) and detailed content confirm it is not a mere announcement but a full current report filing.
2021-01-22 English
FORM 8-K
Investor Presentation Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 11, 2021, by Novavax, Inc. It reports an update provided at the 39th Annual J.P. Morgan Healthcare Conference, specifically an Investor Presentation related to the company's coronavirus vaccine candidate. The text explicitly states that the Investor Presentation is attached as Exhibit 99.1 and is incorporated by reference. The document is primarily an announcement of the presentation and includes cautionary forward-looking statements. There are no detailed financial statements or comprehensive analysis within the text itself, only a reference to the presentation. Given the nature of the content and the explicit mention of an Investor Presentation, the correct classification is Investor Presentation (IP). The document length is 4928 characters, which is sufficient to include substantive content but the main content is the announcement and inclusion of the presentation, consistent with an IP filing.
2021-01-11 English
FORM 4 SUBMISSION
Director's Dealing
2021-01-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.